SCHEMBL25754413

SCHEMBL25754413

CC#CC(N)CCOCCN1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.36
HRH3 Q9Y5N1 6/20 0.34
KDM4E B2RXH2 4/20 0.34
HTT P42858 3/20 0.34
PSMB1 P20618 1/20 0.34
PSMB5 P28074 1/20 0.34
ALDH1A1 P00352 3/20 0.33
KMT2A Q03164 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRA2C P18825 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A4 P31645 1/20 0.33
HRH1 P35367 1/20 0.33
SLC6A3 Q01959 1/20 0.33
KCNH2 Q12809 1/20 0.33
CACNA1C Q13936 1/20 0.33
SCN5A Q14524 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754436 0.98 KDM4E (0.36) MAPTHRH3KDM4EHTTPSMB1
SCHEMBL25754416 0.91 HRH3 (0.38) MAPTHRH3KDM4EHTTCHRM2
SCHEMBL25754417 0.86 HTT (0.39) MAPTHRH3KDM4EHTTPSMB1
SCHEMBL25754394 0.86 HRH3 (0.35) MAPTHRH3KDM4EHTTPSMB1
SCHEMBL25754591 0.83 HRH3 (0.38) MAPTHRH3KDM4EHTTPSMB1
SCHEMBL25754249 0.83 HRH3 (0.38) MAPTHRH3KDM4EHTTPSMB1
SCHEMBL25754258 0.81 KDM4E (0.39) MAPTHRH3KDM4EHTTPSMB1
SCHEMBL25754525 0.77 HRH3 (0.32) HRH3ALDH1A1CHRM2ADRA2CSLC6A2
SCHEMBL25754498 0.76 HRH3 (0.33) HRH3KDM4EPSMB1PSMB5ALDH1A1
SCHEMBL25754250 0.76 HRH3 (0.39) MAPTHRH3KDM4EALDH1A1CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 MAPT 1198/4885HRH3 1596/4885KDM4E 2658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.